secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001564590-22-027257
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q2 revenue up 151% to $20.5M, raises 2022 guidance to $67M-$75M
---------------------------------------------------------------------------

- Net revenue $20.5M in Q2 2022 vs $8.2M a year ago (+151%); gross margin improved to 70% from 68%.
- Net loss of $11.5M vs $10.7M in Q2 2021; operating expenses rose to $24.1M from $15.5M.
- Entered $60M five-year loan with CIBC, replacing $35M OrbiMed facility; netted $23M cash.
- Full-year 2022 revenue guidance raised to $67M-$75M (prior $59M-$65M), representing 121%-148% YoY growth.
- National OCS Program drove 84% of US revenue; integrated OCS Heart DCD into NOP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/0001564590-22-027257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000156459022027257/tmdx-8k_20220801.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-027257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer